Rapid development of a synthetic DNA vaccine for COVID-19
Authors: Smith et al.
Link to paper: https://www.researchsquare.com/article/rs-16261/v1
Journal/ Pre-Print: Researchsquare
This study tests the efficacy of existing synthetic plasmid DNA (pDNA) backbone-based vaccine technology against the SARS-Cov-2 spike protein that contains the receptor binding domain (RBD) of the virus. Vaccines against the analogue spike in SARS-Cov are already being clinically tested. In this study, the authors use the same plasmid backbone to develop a SARS-Cov-2 vaccine. The vaccine is administered intramuscularly into mice and guinea pigs by electroporation. In both species there is a measurable humoral response against recombinant spike protein after 14 days. T cell response was also detected in mice with ELISpot against SARS-Cov-2 peptides.
- pDNA vaccines can elicit humoral responses against recombinant SARS-Cov-2 spike in small rodents.
- pDNA vaccines can elicit cellular response against recombinant SARS-Cov-2 spike in mice.
- pDNA vaccines with the same plasmid backbones have already been tested in humans.
For development of a SARS-Cov-2 vaccine that can be rapidly produced at scale
DNA vaccine development (plasmid cloning)
In vitro RNA expression
In vitro protein expression (Western blot, immunofluorescence)
In vivo (mice and guinea pigs) electroporation
Antigen binding assay (ELISA)
Cell activation assay (ELISpot)
STRENGTHS AND WEAKNESSES OF THE PAPER:
Quality of the assays
Feasible as there are similar vaccines already in the clinic
Intramuscular delivery system requires special device
Low number of animals used
Conflict of interest: Coalition for Epidemic Preparedness Innovations (CEPI)
Using recombinant protein instead of the virus
No infection outcome readout